ASO and CRISPR/Cas13 have been evaluated in HD animal models over a wide range of treatment durations from 1 week to several months and have been reported to improve neurological symptoms by eliminating mutant HTT mRNA (59, 82, 83) but have not yet been clinically successful. This evidence concerns the gene HTT and Huntington disease.